LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
Latest Information Update: 24 Jun 2025
At a glance
- Drugs Pembrolizumab (Primary) ; Platinum complexes (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms LUNAR-2
- Sponsors Bio-America
Most Recent Events
- 04 Jun 2024 Status changed from not yet recruiting to recruiting.
- 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 24 Apr 2024 According to a Novocure Limited media release, data from this study will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4.